Literature DB >> 18729009

Apixaban, an oral, direct inhibitor of activated Factor Xa.

Eduard Shantsila1, Gregory Y H Lip.   

Abstract

Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18729009

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  11 in total

Review 1.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

Review 2.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 3.  Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs.

Authors:  Ipek Celikyurt; Christoph R Meier; Michael Kühne; Beat Schaer
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

Review 4.  Newer anticoagulants in 2009.

Authors:  Meyer Michel Samama; Grigoris T Gerotziafas
Journal:  J Thromb Thrombolysis       Date:  2010-01       Impact factor: 2.300

5.  Emergency reversal of antithrombotic treatment.

Authors:  Marcel Levi
Journal:  Intern Emerg Med       Date:  2008-11-12       Impact factor: 3.397

6.  Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations.

Authors:  Lars C Borris
Journal:  J Blood Med       Date:  2010-07-05

Review 7.  Primary prevention of venous thromboembolism in medical and surgical oncology patients.

Authors:  A Stanley; A Young
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

Review 8.  New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events.

Authors:  Ymer H Mekaj; Agon Y Mekaj; Shkelzen B Duci; Ermira I Miftari
Journal:  Ther Clin Risk Manag       Date:  2015-06-24       Impact factor: 2.423

Review 9.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20

Review 10.  Anticoagulant therapy in pediatrics.

Authors:  Mariam K Dabbous; Fouad R Sakr; Diana N Malaeb
Journal:  J Basic Clin Pharm       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.